Rheumatoid arthritis
Conditions
Interventions
Patients retaining LDA with the combination of CZP and MTX are randomized to two groups consisting of patients who continue MTX at the same doses or discontinue MTX. The effects of both groups are com
Sponsors
Miyazaki Yusuke
Tanaka Yoshiya
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients aged over 16 years (at the time of informed consent) 2) Patients diagnosed with rheumatoid arthritis (RA) under the 1987 American College of Rheumatology (ACR) or 2010 ACR/European League Against Rheumatism (EULAR) criteria 3) Patients who have been receiving combination therapy with MTX ( over 6 mg/week) and CZP for 24 weeks before enrollment of the study 4) Patients who showed SDAI less than 11 at any visit for over 3 months before enrollment without taking any steroids 5) Patients who provided written informed consent
Exclusion criteria
Exclusion criteria: Patients judged by the investigator to be unsuitable for participants in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients with SDAI less than 11 at 12, 24, and 52 weeks after starting the study | — |
Secondary
| Measure | Time frame |
|---|---|
| SDAI remission rate at 52 weeks after starting the study DAS28-ESR remission rate at 52 weeks after starting the study Duration of protocol therapy Change from baseline in the mTSS at 52 weeks after starting the study | — |
Contacts
Public ContactYusuke Miyazaki
Hospital of the University of Occupational and Environmental Health, Japan
Outcome results
None listed